top of page

Basilea Pharmaceutica

Portfolio update

Dr Brian White

Andrew Keith


5 January 2024

Screenshot 2024-01-05 at 16.09.37.png
Screenshot 2024-01-05 at 16.11.24.png

Basilea has provided a timely reminder of the ongoing robust performance of the existing anti-infectives portfolio, along with a recapitulation of plans for 2024. For us, one of the most important aspects of delivery in 2023 has been management executing its prime objective to replenish the anti-infective pipeline and, in particular, provide longevity to the antifungal pipeline post the expected expiration of exclusivity for Cresemba in Q4 2027 in the US and Europe. Nevertheless, it would be unfair to overlook the continued excellent performance of Cresemba, with end-market sales of $445m in the 12 months to the end of September 2023, representing a truly impressive 22% increase year-over-year. Importantly, Cresemba remains early in its launch phase in potentially significant markets like China and Japan, providing a strong financial platform even beyond 2027.


Impressive in-licensing activity

The acquisition of rights to the novel first in (gepix) class antifungal fosmanogepix represents a significant coup for Basilea. The profile of fosmanogepix appears very attractive, with numerous appealing characteristics. It is highly selective and offers good oral bioavailability. It has a broad spectrum against various Aspergillus and Candida, including those resistant to the echinocandins. Its importance has been reflected in FDA conferring Fast Track status for various invasive fungal infections, including aspergillosis, candidiasis, and mucormycosis. Fosmanogepix has already been studied extensively, including three open-label phase 2 studies for the treatment of candidemia, including Candida auris and invasive moulds. Data have been very promising, with activity against difficult-to-treat fungi and a good side effect profile suggesting that the Phase 3 programme has been substantially de-risked. The Phase 3 programme is scheduled to begin in mid-2024, suggesting that much will be known about its potential prior to the key Cresemba 2027 period.


Increasing importance of anti-bacterial franchise

Basilea also entered into a licensing and option agreement for the novel anti-bacterial endolysin tonabacase. Endolysins have recently enjoyed renewed interest because of mounting resistance concerns regarding commonly used antibiotics. They also represent attractive anti-bacterial agents as they have activity against resistant bacteria like MRSA and biofilms and have demonstrated synergy with antibiotics. Encouragingly, tonabacase has undergone Phase 1 clinical evaluation, where it was shown to be well tolerated. Should tonabacase successfully complete Basilea's preclinical studies, it has the potential to directly enter Phase 2 studies as early as 2025. Elsewhere, ceftobiprole’s forthcoming US approval (action date April 3rd) has been long awaited, and we expect the approval, along with securing a commercial partner to be another important de-risking event. Our forecasts suggest that peak sales in the US alone could approach $400m. Hopefully emboldened by success to date we note that it remains Basilea’s objective to further strengthen the anti-infectives franchise by continuing to expand the company’s R&D portfolio through the “…identification of innovative, commercially attractive assets, addressing unmet medical needs in the treatment of severe fungal and bacterial diseases”.


There are exciting times ahead.

After recent acquisition and in-licensing activity, our financial forecasts and fair value are under review.


Calvine Partners LLP is authorised and regulated by the Financial Conduct Authority in respect of UK investment advisory and arranging activities.


This publication has been commissioned and paid for by Basilea Pharmaceutica and as defined by the FCA is not independent research. This report is considered to be a marketing communication under FCA rules, and it has not been prepared under the laws and requirements established to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. The information provided is widely available to the public.


This report in the United Kingdom is directed at investment professionals, certified high net worth individuals, high net worth entities, self-certified sophisticated investors, eligible counterparties as defined by Financial Services and Markets Act 2000 (Financial Promotion) Order 2000. The report may also be distributed and made available to persons to whom Calvine Partners is lawfully permitted. This publication is not intended for use by any individual or entity in any jurisdiction or country where that use would breach law or regulations, or which would subject Calvine Partners or its affiliates to any registration requirement within such jurisdiction or country.


Calvine Partners may provide, or seek to provide, services to other companies mentioned in this report. Partners, employees, or related parties thereof may hold positions in the companies mentioned in the report subject to Calvine Partners’ personal account dealing rules.


Calvine Partners has only used publicly available information believed to be reliable at the time of this publication and made best efforts to ensure that the facts and opinions stated are fair, accurate, timely and complete at the publication date. However, Calvine Partners provides no guarantee concerning the accuracy or completeness of the report or the information or opinions within. This publication is not intended to be an investment recommendation, personal or otherwise, and it is not intended to be advice and should not be treated in any way as such. Any valuation estimates, such as those derived from a discounted cash flow, price multiple, or peer group comparison, do not represent estimates or forecasts of a future company share price. In no circumstances should the report be relied on or acted upon by non-qualified individuals. Personal or otherwise, it is not intended to be advice and should not be relied on in any way as such. 


Forward-looking statements, information, estimates and assumptions contained in this report are not yet known, and uncertainties may cause the actual results, performance or achievements to be significantly different from expectations.


This report does not constitute an offer, invitation or inducement to engage in a purchase or sale of any securities in the companies mention. The information provided is for educational purposes only and this publication should not be relied upon when making any investment decision or entering any commercial contract. Past performance of any security mentioned is not a reliable indicator of future results and readers should seek appropriate, independent advice before acting on any of the information contained herein. This report should not be considered as investment advice, and Calvine Partners will not be liable for any losses, costs or damages arising from the use of this report. The information provided in this report should not be considered in any circumstances as personalised advice.


Calvine Partners LLP, its affiliates, officers or employees, do not accept any liability or responsibility with regard to the information in this publication. None of the information or opinions in this publication has been independently verified. Information and opinions are subject to change after the publication of this report, possibly rendering them inaccurate and/or incomplete.


Any unauthorised copying, alteration, distribution, transmission, performance, or display, of this report, is prohibited.

bottom of page